Adamax

Adamax is a synthetic octapeptide with the sequence Ac-MEHFPGPAG-NH2 (molecular formula approximately C50H69N11O11S, about 1032 g/mol). It is a designer analogue of Semax, a peptide derived from a fragment of the hormone ACTH that has been studied in Russia as a nootropic. Adamax takes the Semax-style core and adds chemical modifications at both ends of the molecule, including N-terminal acetylation and C-terminal amidation (the latter borrowing structural features from another experimental peptide, P21). The stated purpose of these changes is to make the peptide more resistant to the enzymes that normally break down peptides in the body, with the intent of extending how long it lasts.

Vendors and enthusiast write-ups claim Adamax acts as a potent nootropic and neuroprotective agent, typically describing effects on brain-derived neurotrophic factor (BDNF) and other neurotrophic and cognitive pathways. It is important to understand that these claims are extrapolated from what is reported about Semax, the parent peptide; they are a structural and theoretical rationale, not findings demonstrated for Adamax. Because Adamax is a distinct, modified molecule, effects observed with Semax cannot be assumed to carry over, and none of the marketed cognitive or neuroprotective effects have been established for Adamax in published research.

The honest evidence picture is that there is essentially no dedicated published research on Adamax: no human or clinical trials, and no notable dedicated animal or laboratory studies of the compound itself. Adamax is not approved as a medicine anywhere and has been encountered as a designer drug in border seizures. In June 2025, New Zealand's Medsafe identified it as an analogue of ACTH and proposed classifying it (within a group entry covering such analogues) as a prescription medicine, citing nootropic marketing claims, limited clinical data, and an unknown safety profile. Its safety in humans is unknown.